ADA Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant ADA.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB |
|---|---|
| Primary Accession | P00813 |
| Other Accession | BC040226 |
| Reactivity | Human |
| Host | mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 Kappa |
| Clone Names | 4G4-1C6 |
| Calculated MW | 40764 Da |
| Gene ID | 100 |
|---|---|
| Other Names | Adenosine deaminase, Adenosine aminohydrolase, ADA, ADA1 |
| Target/Specificity | ADA (AAH40226.1, 1 a.a. ~ 363 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | ADA Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia.
References
An indication for correlation between the serum ADA level and gastric cancer risk. Ri G, et al. Anticancer Res, 2010 Jun. PMID 20651391.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Levine AJ, et al. Cancer Epidemiol Biomarkers Prev, 2010 Jul. PMID 20615890.A Study of Three Polymorphic Sites of ADA Gene in Colon Cancer. Spina C, et al. Cancer Invest, 2010 Jun 30. PMID 20590444.The interaction of ACP1, ADA1, diabetes and gender in coronary artery disease. Gloria-Bottini F, et al. Am J Med Sci, 2010 Aug. PMID 20581655.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.




